Schedule 1—Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

Note: See sections 5, 6 and 6A.

Permissible ingredients and requirements			
Column 1	**Column 2**	**Column 3**	**Column 4**
Item	**Ingredient Name**	**Purpose**	**Specific requirements**
5073	UBIDECARENONE	A, E	When used as an excipient, the route of administration must be topical and the concentration in the medicine must not be more than 0.05%. Not to be included in medicines intended for use in the eye. When for internal use, the maximum recommended daily dose must not provide more than 300 milligrams of ubidecarenone. When for internal use in combination with Ubiquinol-10, the maximum recommended daily dose must not provide more than 300 milligrams of ubiquinol-10 and ubidecarenone combined. When for internal use, the following warning statement is required on the medicine label: - (WARF) 'Do not take while on warfarin therapy without medical advice'.
5074	UBIQUINOL-10	A, E	When used as an excipient, the route of administration must be topical and the concentration in the medicine must be no more than 0.05%. Not to be included in medicines intended for use in the eye. When for internal use, the maximum recommended daily dose must provide no more than 300 milligrams of ubiquinol-10. When used in combination with ubidecarenone, the maximum recommended daily dose must provide no more than 300 mg of ubiquinol-10 and ubidecarenone combined.

Volume 6

			The medicine requires the following warning statement on the medicine label: - (WARF) 'Do not take while on warfarin therapy without medical advice.'
5075	ULEX EUROPAEUS	A, H	
5076	ULMUS AMERICANA	A, H	
5077	ULMUS CAMPESTRIS	A, H	
5078	ULMUS GLABRA	A, H	
5079	ULMUS MINOR	A, H	
5080	ULMUS PARVIFOLIA	A, H	
5081	ULMUS PUMILA	A, H	
5082	ULMUS RUBRA	A, H	
5083	ULTRALIDE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
5084	ULTRAMARINE BLUE	E	Permitted for use only as a colour for topical use.
5085	ULVA LACTUCA	A, H	Iodine is a mandatory component of Ulva lactuca. Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.1%.
5086	UMBELLULARIA CALIFORNICA	A, H	
5087	UNCARIA GAMBIR	A, H	
5088	UNCARIA RHYNCOPHYLLA	A, H	
5089	UNCARIA SINENSIS	A, H	
5090	UNCARIA TOMENTOSA	A, H	
5091	UNDARIA PINNATIFIDA	A, H	Whole dried Undaria pinnatifida must not contain the holdfast. Only for use in oral medicines.
5092	UNDECANAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

			If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
5093	UNDECANOIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used as a flavour the total flavour concentration in a medicine must be no more than 5%.
5094	UNDECENOIC ACID	E	
5095	UNDECYL ALCOHOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
5096	UNDECYLCRYLENE DIMETICONE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 10%.
5097	UNDECYLENAMIDE DEA	E	
5098	UNDECYLENOYL PEG-5 PARABEN	E	Only for use in topical medicines for dermal application.
5099	URANIUM NITRATE	H	Only for use as an active homoeopathic ingredient.
5100	UREA	A, E, H	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 10% (w/w).
5101	URTICA DIOICA	A, E, H	
5102	URTICA URENS	A, H	

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

Volume 6

5103	USNEA BARBATA	A, H	
5104	UVA URSI LEAF DRY	A, H	
5105	UVA URSI LEAF POWDER	A, E, H	
5106	VA/BUTYL MALEATE/ISOBORNYL ACRYLATE COPOLYMER	E	Vinyl acetate is a mandatory component of VA/butyl maleate/isobornyl acrylate copolymer. The concentration of vinyl acetate in the medicine must be no more than 0.01% or 100 ppm. Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5%.
5107	VACCARIA SEGATALIS	A, H	
5108	VACCINIUM BRACTEATUM	A, H	
5109	VACCINIUM CORYMBOSUM	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
5110	VACCINIUM MACROCARPON	A, E, H	
5111	VACCINIUM MYRTILLOIDES	A, H	
5112	VACCINIUM MYRTILLUS	A, E, H	
5113	VACCINIUM OXYCOCCUS	A, H	
5114	VACCINIUM VITIS-IDAEA	A, H	Beta-arbutin is a mandatory component of Vaccinium vitis-idaea. When for oral use, the maximum recommended daily dose must not provide more than 500 mg of beta-arbutin. When for dermal application exclusively to the face: a) the concentration of beta-arbutin in the medicine must not be more than 7%; b) hydroquinone is a mandatory component; and c) the concentration of hydroquinone must not be more than 10 mg/kg or 10 mg/L or 0.001%. When for use other than oral or dermal application exclusively to the face, the concentration of beta-arbutin in the

			medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%.
5115	VALENCENE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
5116	VALERALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
5117	VALERIAN DRY	A, H	The following warning statement is required on the medicine label when the medicine is for oral use: (VALER) 'In rare cases, valerian may harm the liver. Stop use and see a doctor if you have yellowing skin/eyes or unusual: fatigue, nausea, appetite loss, abdominal pain, dark urine or itching.'
5118	VALERIAN OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
5119	VALERIAN POWDER	A, H	The following warning statement is required on the medicine label when the medicine is for oral use: (VALER) 'In rare cases, valerian may harm the liver. Stop use and see a doctor if you have yellowing skin/eyes or unusual: fatigue, nausea, appetite loss, abdominal pain, dark urine or itching.'
5120	VALERIANA EDULIS	A, H	
5121	VALERIANA OFFICINALIS	A, H	The following warning statement is required on the medicine label when the medicine is for oral use:

			(VALER) 'In rare cases, valerian may harm the liver. Stop use and see a doctor if you have yellowing skin/eyes or unusual: fatigue, nausea, appetite loss, abdominal pain, dark urine or itching.'
5122	VALERIANA SORBIFOLIA	A, H	
5123	VALERIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
5124	VALINE	A, E	
5125	VANADIUM	H	
5126	VANILLA	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
5127	VANILLA DRY	A, E, H	
5128	VANILLA EXTRACT	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
5129	VANILLA OLEORESIN	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
5130	VANILLA PLANIFOLIA	A, E, H	
5131	VANILLA POWDER	A, E, H	
5132	VANILLA TAHITENSIS	A, H	

5133	VANILLIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
5134	VANILLIN	E	
5135	VANILLIN ACETATE	E	Vanillin acetate must only be included in medicines when in combination with other permitted ingredients as a flavour proprietary excipient formulation. The total concentration of flavour proprietary excipient formulations containing vanillin acetate must not be more than 5% of the total medicine. The maximum recommended daily dose of the medicine must not provide more than 1.8 micrograms of vanillin acetate.
5136	VANILLIN ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
5137	VANILLYL ALCOHOL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
5138	VAT RED 1	E	Permitted for use only as a colour for topical use.
5139	VAT RED 1 ALUMINIUM LAKE	E	Permitted for use only as a colour for topical use.
5140	VAT RED 5	E	Permitted for use only as a colour for topical use.

Volume 6

5141	VEGETABLE OIL	E	
5142	VEGETABLE OIL PHYTOSTEROL ESTERS	A	Only for use in oral medicines. The medicine requires the following warning statement on the medicine label: - (PREGNT) 'Not recommended for use by pregnant and lactating women (or words to that effect).'
5143	VEIN	H	Only for use as an active homoeopathic ingredient.
5144	VERATRALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
5145	VERATROL	E	Permitted for use only in combination with other permitted ingredients as part of a fragrance proprietary excipient formulation. The total fragrance proprietary excipient formulation in a medicine must be no more than 1%.
5146	VERATRUM ALBUM	A, H	Solanidine is a mandatory component of Veratrum album. The concentration of equivalent dry Veratrum album in the medicine must be no more than 10mg/Kg or 10mg/L or 0.001%.
5147	VERBASCUM DENSIFLORUM	A, H	
5148	VERBASCUM THAPSUS	A, H	
5149	VERBENA OFFICINALIS	A, H	
5150	VERBENA OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

5151	VERONICA CHAMAEDRYS	A, H	
5152	VERONICA OFFICINALIS	A, H	
5153	VERONICASTRUM VIRGINICUM	A, E, H	
5154	VERTONAL	E	Permitted for use only in combination with other permitted ingredients as part of a fragrance proprietary excipient formulation. When included in a medicine for use on the lips the concentration of vertonal must be no more than 0.2%. The total fragrance proprietary excipient formulation in a medicine must be no more than 1%.
5155	VETIVER OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
5156	VETIVERYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
5157	VIBURNUM OPULUS	A, E, H	
5158	VIBURNUM PRUNIFOLIUM	A, E, H	
5159	VICIA FABA	A, H	Levodopa is a mandatory component of Vicia faba. The concentration of levodopa in the medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%.
5160	VIGNA ANGULARIS VAR. ANGULARIS	A, H	
5161	VIGNA RADIATA	A, H	
5162	VIGNA UMBELLATA	A, H	
5163	VINCA MAJOR	A, H	Vincamine is a mandatory component of Vinca major.

Volume 6

			The concentration of vincamine in the medicine must be no more than 10mg/kg or 10 mg/L or 0.001%.
5164	VINCA MINOR	A, H	Vincamine and vincristine are mandatory components of Vinca minor. The concentration of vincamine in the medicine must be no more than 10mg/kg or 10 mg/L or 0.001%. The concentration of Vincristine in the medicine must be no more than 10mg/kg or 10mg/L or 0.001%
5165	VINCETOXICUM OFFICINALE	A, H	
5166	VINEGAR	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
5167	VIOLA ODORATA	A, E, H	
5168	VIOLA TRICOLOR	A, H	
5169	VIOLA YEDOENSIS	A, H	
5170	VIOLET LEAF ABSOLUTE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
5171	VIPER	H	Only for use as an active homoeopathic ingredient.
5172	VISCUM ALBUM	A, E, H	
5173	VISCUM COLORATUM	A, H	
5174	VISCUM FLAVESCENS	A, H	
5175	VITELLARIA PARADOXA	A, E, H	
5176	VITEX AGNUS-CASTUS	A, E, H	When the ingredient is in a medicine that is for internal use, the following warning statement is required on the label:

			- (VAC) 'Vitex agnus-castus may affect hormones and medicines such as oral contraceptives. Consult your health professional before use' (or words to that effect).
5177	VITEX NEGUNDO	A, H	
5178	VITEX ROTUNDIFOLIA	A, H	
5179	VITEX TRIFOLIA	A, H	
5180	VITIS VINIFERA	A, E, H	
5181	VITREOSCILLA CONCENTRATE	E	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 0.1%.
5182	VP/ACRYLATES/LAURYL METHACRYLATE COPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must not be more than 2.00%.
5183	WAHLENBERGIA GRACILIS	A, H	
5184	WALNUT	E	
5185	WALNUT OIL	E	
5186	WHEAT	E	Gluten is a mandatory component of Wheat when the route of administration is other than topical and mucosal.
5187	WHEAT BRAN	E	Gluten is a mandatory component of Wheat bran when the route of administration is other than topical and mucosal.
5188	WHEAT DEXTRIN	A, E	Gluten is a mandatory component of wheat dextrin. Only for use when the dosage form is capsule, tablet or pill.
5189	WHEAT GERM	E	Gluten is a mandatory component of Wheat germ when the route of administration is other than topical and mucosal.

Volume 6

5190	WHEAT GERM GLYCERIDES	E	Gluten is a mandatory component of wheat germ glycerides when the route of administration is other than topical and mucosal.
5191	WHEAT LEAF	E	
5192	WHEAT STARCH	E	When the route of administration is other than topical or mucosal, gluten is a mandatory component of wheat starch.
5193	WHEATGERM OIL	A, E, H	
5194	WHEY POWDER	E	Lactose is a mandatory component of Whey powder when the route of administration is oral.
5195	WHEY PROTEIN	E	Lactose is a mandatory component of Whey protein when the route of administration is oral.
5196	WHEY PROTEIN CONCENTRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
5197	WHITE BEESWAX	E	
5198	WHITE HOREHOUND HERB DRY	A, H	
5199	WHITE HOREHOUND HERB POWDER	A, H	
5200	WHITE SOFT PARAFFIN	A, E	When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.
5201	WHOLE DRY MILK	E	
5202	WIKSTROEMIA VIRIDIFLORA	A, H	
5203	WILD CARROT HERB DRY	A, E, H	
5204	WILD CARROT HERB POWDER	A, H	
5205	WILD CHERRY BARK DRY	A, H	Amygdalin and hydrocyanic acid are mandatory components of wild cherry bark dry.

			The concentration of amygdalin in the medicine must not be more than 10 mg/kg. The concentration of hydrocyanic acid in the medicine must not be more than 10 mg/kg.
5206	WILD CHERRY BARK POWDER	A, H	Amygdalin and hydrocyanic acid are mandatory components of wild cherry bark powder. The concentration of amygdalin in the medicine must not be more than 10 mg/kg. The concentration of hydrocyanic acid in the medicine must not be more than 10 mg/kg.
5207	WILD LETTUCE LEAF DRY	A, H	
5208	WILD LETTUCE LEAF POWDER	A, H	
5209	WINTERGREEN OIL	A, E, H	Methyl salicylate is a mandatory component of wintergreen oil. Not to be included in medicines for use in the eye or on damaged skin. When used internally, the concentration of methyl salicylate in the medicine must not be more than 0.001%. When the concentration of methyl salicylate in a liquid preparation is more than 5% and the dosage form is other than spray, the medicine requires child resistant packaging. When the concentration of methyl salicylate in a liquid preparation is more than 5%, and the dosage form is spray, the medicine does not require child resistant packaging if: - the delivery device is engaged into the container in such a way that prevents it from being readily removed; - direct suction through the delivery device results in delivery of no more than one dosage unit; and - actuation of the spray device is ergonomically difficult for young children to accomplish. The following warning statement is required on the medicine label:

			- (METSAL) 'Contains methyl salicylate' (or words to that effect). When for use in topical medicines for dermal application: i) the concentration of methyl salicylate in the medicine must not be more than 25%; ii) the following warning statements are required on the medicine label: - (PREGNT2) 'Do not use if pregnant or likely to become pregnant' (or words to that effect); - (CHILD4) 'Do not use [this product/insert name of product] in children 6 years of age or less'; - (SENS) 'Application to skin may increase sensitivity to sunlight' (or words to that effect); - (AVOID) 'Avoid prolonged exposure in the sun' (or words to that effect); iii) if the concentration of methyl salicylate in the medicine is greater than 1%, the following warning statement is required on the medicine label: - (IRRIT) 'If irritation develops, discontinue use'.
5210	WITHANIA SOMNIFERA	A, E, H	The medicine requires the following warning statement on the label: - (WITHANIA) 'If you are pregnant, or considering becoming pregnant, do not take without consulting a health professional' (or words to that effect) unless: (a) the plant part is root; (b) the plant preparation is an extract; (c) the extraction solvents are only water, ethanol or methanol; and (d) the maximum recommended daily dose of the medicine contains no more than the equivalent quantity of 12 g dry root.
5211	WOLFIPORIA COCOS	A, E, H	
5212	WOOL ALCOHOLS	E	Only for use in topical medicines for dermal application.

5213	WOOL FAT	A, E	When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.
5214	XANTHAN GUM	E	
5215	XANTHIUM SIBIRICUM	A, H	The requirements specified in paragraphs (a) to (h) below apply to a medicine that contains the ingredient that is: - listed in the Register on or after 1 March 2025; or - released for supply on or after 1 March 2026. (a) Carboxyatractyloside and atractyloside are mandatory components of Xanthium sibiricum. (b) The concentration of carboxyatractyloside must not be more than 0.35% of Xanthium sibiricum. (c) The concentration of atractyloside must not be more than 0.3% of Xanthium sibiricum. (d) The route of administration for medicines that contain Xanthium sibiricum must be limited to oral. (e) The plant part must be limited to fruit that is dried, cooked and had the spines removed. (f) The plant preparation must be limited to dry, powder, and extraction preparations with water as the only solvent. (g) The maximum recommended daily dose of the medicine must not provide more than 10 g of Xanthium sibiricum. (h) The medicine must not be directed for use in children, those who are pregnant, likely to become pregnant, or lactating.
5216	XANTHIUM STRUMARIUM	A, H	The requirements specified in paragraphs (a) to (h) below apply to a medicine that contains the ingredient that is: - listed in the Register on or after 1 March 2025; or

			- released for supply on or after 1 March 2026. (a) Carboxyatractyloside and atractyloside are mandatory components of Xanthium strumarium. (b) The concentration of carboxyatractyloside must not be more than 0.35% of Xanthium strumarium. (c) The concentration of atractyloside must not be more than 0.3% of Xanthium strumarium. (d) The route of administration for medicines that contain Xanthium strumarium must be limited to oral. (e) The plant part must be limited to fruit that is dried, cooked and had the spines removed. (f) The plant preparation must be limited to dry, powder, and extraction preparations with water as the only solvent. (g) The maximum recommended daily dose of the medicine must not provide more than 10 g of Xanthium strumarium. (h) The medicine must not be directed for use in children, those who are pregnant, likely to become pregnant, or lactating.
5217	XANTHOMONA CAMPESTRIS	A, H	
5218	XEROPHYLLUM ASPHODELOIDES	A, H	
5219	XYLENE	E	The residual solvent limit for xylene is 21.7 mg per maximum recommended daily dose. The concentration in the medicine must be no more than 0.217%.
5220	XYLITOL	E	
5221	XYLOSE	E	
5222	YAM	E	
5223	YARROW HERB DRY	A, H	
5224	YARROW HERB POWDER	A, H	
5225	YEAST AUTOLYSATE	E	
5226	YEAST DRIED	A, E, H	
5227	YELLOW 2G	E	Permitted for use only as a colour for topical use.

5228	YELLOW BEESWAX	E	
5229	YELLOW MERCURIC OXIDE	H	Only for use as an active homoeopathic ingredient.
5230	YELLOW SOFT PARAFFIN	A, E	Only for use in topical medicines for dermal application. When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.
5231	YLANG YLANG OIL	A, E, H	
5232	YUCCA BACCATA	A, H	
5233	YUCCA ELATA	A, H	
5234	YUCCA FILAMENTOSA	A, H	
5235	YUCCA GLORIOSA	A, H	
5236	Z-BETA-DAMASCONE	E	Z – beta damascone must only be included in medicines when in combination with other permitted ingredients as a flavour proprietary excipient formulation. The total concentration of flavour proprietary excipient formulations containing Z – beta damascone must not be more than 5% of the total medicine.
5237	ZANTHOXYLUM AMERICANUM	A, H	
5238	ZANTHOXYLUM BUNGEANUM	A, E, H	
5239	ZANTHOXYLUM CLAVA-HERCULIS	A, H	
5240	ZANTHOXYLUM NITIDUM	A, H	
5241	ZANTHOXYLUM PIPERITUM	A, H	
5242	ZANTHOXYLUM SIMULANS	A, H	
5243	ZEA MAYS	A, E, H	
5244	ZEAXANTHIN	A, E	
5245	ZEIN	E	
5246	ZINC	H	Only for use as an active homoeopathic ingredient. When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc.

Volume 6

			When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect)'.
5247	ZINC AMINO ACID CHELATE	A, E, H	When used internally, zinc is a mandatory component of zinc amino acid chelate. The concentration of zinc in zinc amino acid chelate must be no more than 30%. When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).'
5248	ZINC ASCORBATE	A, E, H	When used internally, zinc is a mandatory component of zinc ascorbate. When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).'
5249	ZINC ASCORBATE MONOHYDRATE	A, E, H	When used internally, zinc is a mandatory component of zinc ascorbate monohydrate.

			When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect)'.
5250	ZINC CHLORIDE	A, E, H	The concentration of zinc chloride in the medicine must be no more than 5%. When used internally, zinc is a mandatory component of zinc chloride. When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).'
5251	ZINC CITRATE	A, E, H	When used internally, zinc is a mandatory component of zinc citrate. When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if

			taken in large amounts or for a long period (or words to that effect).'
5252	ZINC CITRATE DIHYDRATE	A, E, H	When used internally, zinc is a mandatory component of zinc citrate dihydrate. When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).'
5253	ZINC CITRATE TRIHYDRATE	A, E, H	When used internally, zinc is a mandatory component of zinc citrate trihydrate. When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).'
5254	ZINC DIASPARTATE	A	When used internally, zinc is a mandatory component of zinc diaspartate. When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label:

			- (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).'
5255	ZINC GLUCONATE	A, E, H	When used internally, zinc is a mandatory component of zinc gluconate. When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).'
5256	ZINC GLYCINATE	A	When used internally, zinc is a mandatory component of Zinc glycinate. When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).'
5257	ZINC GLYCINATE MONOHYDRATE	A	When used internally, zinc is a mandatory component of Zinc glycinate monohydrate. When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc.

Volume 6

			When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect)'.
5258	ZINC LACTATE	E	Only for use in topical and dental medicines and not to be included in medicines intended for use in the eye. The concentration of zinc lactate in a medicine intended for topical use should not be more than 2%. The concentration of zinc lactate in a medicine for 'dental' use in toothpaste medicines must not be more than 2.5%. Zinc lactate is not to be included in dental/toothpaste medicines intended for use by children less than 12 years old. Medicines containing zinc lactate for dental use require the following warning statement (or words to the same effect) on the medicine label: - (CHILD3) 'Use in children under 12 years is not recommended'.
5259	ZINC LACTATE DIHYDRATE	E	Only for use in topical and dental medicines and not to be included in medicines intended for use in the eye. The concentration of zinc lactate dihydrate in a medicine intended for topical use should not be more than 2%. The concentration of zinc lactate dihydrate in a medicine for 'dental' use in toothpaste medicines must not be more than 2.5%. Zinc lactate dihydrate is not to be included in dental/toothpaste medicines intended for use by children less than 12 years old. Medicines containing zinc lactate dihydrate for dental use require the

			following warning statement (or words to the same effect) on the medicine label: - (CHILD3) 'Use in children under 12 years is not recommended'.
5260	ZINC LYSINATE	A	When used internally, zinc is a mandatory component of Zinc lysinate. When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).'
5261	ZINC METHIONINE SULFATE	A	For topical use, the concentration of zinc methionine sulfate must be no more than 5%. When used internally, zinc is a mandatory component of zinc methionine sulfate. When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).'
5262	ZINC MYRISTATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.1%.

Volume 6

5263	ZINC OXIDE	A, E, H	When used internally, zinc is a mandatory component of zinc oxide. When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR -'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period' (or words to that effect). When used in primary sunscreen products, the following warning statements are required on the label: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
5264	ZINC PARA-PHENOLSULFONATE	E	Only permitted for use in topical medicines for dermal use. The concentration of zinc para-phenolsulfonate in the medicine must not exceed 5%.
5265	ZINC STEARATE	E	When used internally, zinc is a mandatory component of zinc stearate. The percentage of zinc from zinc stearate should be calculated based on the molecular weight of zinc stearate. When for internal use, the maximum recommended daily dose must not provide more than 50 milligrams of zinc. When for internal use and the maximum recommended daily dose is more than 25 milligrams but not more than 50 milligrams of zinc, the medicine requires the following warning statement (or words to the same effect) on the medicine label: - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period'; or

			‘WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period’.
5266	ZINC SUCCINATE	A, E, H	When used internally, zinc is a mandatory component of zinc succinate. When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' or - 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).'
5267	ZINC SULFATE	A, E	For topical use, the concentration of zinc sulfate must be no more than 5%. For internal use, zinc is a mandatory component of zinc sulfate. When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR - 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).'
5268	ZINC SULFATE HEPTAHYDRATE	A, E	For topical use, the concentration of zinc sulfate must be no more than 5%. For internal use, zinc is a mandatory component of zinc sulfate heptahydrate.

Volume 6

			When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR - 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).'
5269	ZINC SULFATE HEXAHYDRATE	A, E, H	For topical use, the concentration of zinc sulfate must be no more than 5%. For internal use, zinc is a mandatory component of zinc sulfate hexahydrate. When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. When for internal use and the maximum recommended daily dose is more than 25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR - 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).'
5270	ZINC SULFATE MONOHYDRATE	A, E, H	When the route of administration is topical the concentration of zinc sulfate in the medicine must be no more than 5%. When the medicine is for internal use, zinc is a mandatory component of zinc sulfate monohydrate. When for internal use, the maximum recommended daily dose must be no more than 50mg of zinc. When for internal use and the maximum recommended daily dose is more than

			25mg but no more than 50mg of zinc, the medicine requires the following warning statement on the medicine label: - (ZINC) 'WARNING: May be dangerous if taken in large amounts or for a long period.' OR - 'WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).'
5271	ZINC VALERATE	H	Only for use as an active homoeopathic ingredient. When for internal use, zinc is a mandatory component of zinc valerate. The percentage of zinc from zinc valerate should be calculated based on the molecular weight of zinc valerate. When for internal use, the maximum recommended daily dose must not provide more than 50 milligrams of zinc. When for internal use and the maximum recommended daily dose is more than 25 milligrams but not more than 50 milligrams of zinc, the medicine requires the following warning statement (or words to the same effect) on the medicine label: - (ZINC) ‘WARNING: May be dangerous if taken in large amounts or for a long period’; or ‘WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period’.
5272	ZINGERONE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
5273	ZINGIBER OFFICINALE	A, E, H	When for oral use AND the extract ratio is equal to or more than 25:1 AND the equivalent dry weight per dosage unit is equal to or more than 2g, the medicine requires the following warning statement on the medicine label:

Volume 6

			- (GINGER) 'Individuals taking anticoagulants should seek medical advice before taking this medicine.' AND 'Individuals at risk of bleeding problems should seek advice from their healthcare practitioner prior to taking this medicine'.
5274	ZIZIPHUS JUJUBA	A, H	
5275	ZIZIPHUS JUJUBA VAR. SPINOSA	A, H	
5276	ZIZYPHUS SATIVA	A, H	
5277	ZOSTERA MARINA	A, H	